Enregistrement du document de base

!
!
!
Ce#document#ne#constitue#pas#une#offre#de#vente#des#actions#ou#autres#titres#financiers#de#OSE#PHARMA#ou#une#quelconque#sollicitation#d’achat#ou#de#
souscription#de#titres#financiers#aux#Etats?Unis#d’Amérique#ni#dans#aucun#autre#pays,#y#compris#au#Canada,#en#Australie#et#au#Japon.#Les#actions#de#OSE#
PHARMA#ne#pourront#être#offertes,#souscrites#ou#vendues#aux#Etats?Unis#d’Amérique#en#l’absence#d’enregistrement#ou#de#dispense#d’enregistrement#au#
titre#du#U.S.#Securities#Act#de#1933,#tel#que#modifié.#OSE#PHARMA#n'envisage#pas#d’enregistrer#l’offre#mentionnée#dans#le#présent#document#ou#une#partie#
de#cette#offre#aux#Etats?Unis#d’Amérique#ni#d'effectuer#une#quelconque#offre#publique#d’actions#aux#Etats?Unis#d’Amérique.#
Ne#pas#distribuer#directement#ou#indirectement#aux#Etats?Unis#d’Amérique,#au#Canada,#en#Australie#ou#au#Japon.#
!
"#$%!&!'()!*!
!
!
!
!
Première!étape!du!projet!d’introduction!en!Bourse!sur!Euronext!Paris!
!
OSE!Pharma!annonce!l’enregistrement!de!son!document!de!base!!
par!l’Autorité!des!Marchés!Financiers!
!
!
OSE!PHARMA!DEVELOPPE!UNE!NOUVELLE!ARME!DE!L’IMMUNOTHERAPIE!CONTRE!LES!CANCERS!
• Memopi®!d’OSE!Pharma!:!une!technologie!spécifique,!innovante!et!brevetée!
• Produit!Texopi®!en!clinique!:!Phase!3!autorisée!dans!le!cancer!du!poumon!aux!USA!et!en!Europe!
• Autres!applications!potentielles!en!Phase!2!(cancers!des!ovaires,!du!colon!et!du!sein)!
!
Paris,!18!septembre!2014!+!OSE!Pharma!SA,!société!biopharmaceutique!qui!développe!des!produits!d’immunothérapie!
spécifique! contre! le! cancer!au! stade! invasif,! annonce! l’enregistrement! de! son! document! de! base! par! l’Autorité! des!
Marchés! Financiers! (AMF),!'-('!.%!/(01)-!.2&*34562! 7%8! %/)%$9'8)%0%/8! 0#):(%! .#! ;)%09<)%! 18#;%! =%! '-/! ;)->%8!
=?9/8)-=(@89-/!%/!A-()'%!'()!B()-/%C8!"#)9',!:(9!'%)#!@-/=(98!'-('!)1'%)D%!=%'!@-/=989-/'!=%!0#)@E1!%8!=%!.#!=1.9D)#/@%!
;#)!.?FGH!=?(/!D9'#!'()!.%!;)-';%@8('!)%.#89I!J!.?-;1)#89-/2!
!
OSE!PHARMA!:!NOUVELLE!ARME!DE!L’IMMUNOTHERAPIE!T!SPECIFIQUE!CONTRE!LES!CANCERS!INVASIFS!
!
KLB!"E#)0#!=1D%.-;;%!=%'!;)-=(98'!=?900(/-8E1)#;9%!@-/8)%!.%'!@#/@%)'!#(!'8#=%!9/D#'9I2!L#!8%@E/-.-$9%!G%0-;9M!
#)0%! .%! 'N'8<0%! 900(/98#9)%!%8!%/!;#)89@(.9%)!.%'!@%..(.%'!O!@N8-8-C9:(%'!;-()!.%!)%/=)%!@#;#A.%!=?1.909/%)!.%'!
@%..(.%'! @#/@1)%('%'!P! %..%! )1#;;)%/=! #(! 'N'8<0%! 900(/98#9)%! J! #88#:(%)! .%'! @%..(.%'! 8(0-)#.%'! %/! #($0%/8#/8! .#!
)1;-/'%!O!';1@9I9:(%2!Q#!010-9)%!900(/-.-$9:(%!%'8!#9/'9!)%8)-(D1%2!Q%'!.N0;E-@N8%'!O!@N8-8-C9:(%'!#@89D1'!'-/8!
#.-)'!;)-$)#001'!;-()!#..%)!=18)(9)%!.%'!@%..(.%'!8(0-)#.%'!)%@-//(%',!%8!%..%'!'%(.%'2!
!
Q?-A>%@89I!=%'!8)#98%0%/8'!(89.9'#/8!G%0-;9M!%'8!=%!'8#A9.9'%)!.%!=1D%.-;;%0%/8!=%!.#!0#.#=9%!%8!=%!;)-.-/$%)!#9/'9!.#!
D9%! =%'! ;#89%/8'2! 7%88%! 9//-D#89-/! )%;)1'%/8%! (/%! -;;-)8(/981! ;-()! .%'! ;#89%/8'! J! ;)-/-'89@! )1'%)D1! -(! %/! 1@E%@!
8E1)#;%(89:(%2!Q%'!#@89I',!.%'!=)-98'!0-/=9#(C!%8!.%!'#D-9)3I#9)%!#''-@91!'-/8!=18%/('!;#)!KLB!"E#)0#2!
!
Q%!;)-=(98!;E#)%!=?KLB!"E#)0#!%'8!O%C-;9M,!(/%!@-0A9/#9'-/!A)%D%81%!=%!&4!1;98-;%'!R;%898%!'8)(@8()%!0-.1@(.#9)%!
:(9!'%!I9C%!J!=%'!)1@%;8%()'!@%..(.#9)%'!%8!:(9!=1@.%/@E%!.#!)1;-/'%!900(/98#9)%!OS2!T.'!-/8!181!'1.%@89-//1'!;#)09!=%'!
09..9%)'!=?1;98-;%',!J!;#)89)!=%!5!#/89$</%'!8(0-)#(C!I)1:(%00%/8!)%8)-(D1'!J!(/!'8#=%!9/D#'9I2!7%'!1;98-;%'!-/8!181!
-;8909'1'!@E909:(%0%/8!;-()!'('@98%)!(/%!)1;-/'%!900(/98#9)%!;.('!I-)8%2!!
!
ETUDE!PIVOT!DE!PHASE!3!DANS!LE!CANCER!DU!POUMON!AUTORISEE!EN!EUROPE!ET!AUX!USA!
!
Q%!;)-=(98!O%C-;9M!#!181!8%'81!%/!"E#'%!U!=#/'!.%!@#/@%)!=(!;-(0-/!.%!;.('!I)1:(%/8,!=98!V!/-/!J!;%898%'!@%..(.%'!W&,!
#(!'8#=%!9/D#'9I!%8!018#'8#'1,!#;)<'!#(!0-9/'!(/%!;)%09<)%!.9$/%!8E1)#;%(89:(%,!%8!;-()!=%'!'(>%8'!XQF3FUY!R*5Z!=%!
.#! ;-;(.#89-/S2! Q%'! )1'(.8#8'! -/8! =10-/8)1! (/%! #($0%/8#89-/! '9$/9I9@#89D%! =%! .#! '()D9%! =%'! ;#89%/8'!@-))1.1%!J!.#!
)1;-/'%!900(/%2!
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
1#Cancer#du#poumon#dit#«#non#à#petites#cellules#souvent#appelé#NSCLC#(non#small#cell#lung#cancer)#–#88%#des#cancers#du#poumon#

!
Ne#pas#distribuer#directement#ou#indirectement#aux#Etats?Unis#d’Amérique,#au#Canada,#en#Australie#ou#au#Japon.#
"#$%!U!'()!*#
7%8!%''#9!#!0-/8)1!(/!8#(C!=%!'()D9%!J!&!#/!=%!5[Z!;-()!.%!$)-(;%!8)#981!#D%@!O%C-;9M2!F(>-()=?E(9,!@%!8#(C!%'8,!;-()!
.%'!8)#98%0%/8'!%/)%$9'8)1'!%/!=%(C9<0%!.9$/%!8E1)#;%(89:(%,!=%!\\ZU2!Q#!01=9#/%!=%!'()D9%!=%'!;#89%/8'!8)#981'!#D%@!
O%C-;9M!%'8!J!&]!0-9',!@-/8)%!&U!0-9'!;-()!.%!$)-(;%!=%!@-/8)^.%2!F!.-/$!8%)0%!R*!#/'S,!.%!8#(C!=%!'()D9%!@-/'8#81%!=%'!
;#89%/8'! 8)#981'!%'8!8)<'! %/@-()#$%/8! %8! #88%9/8!U5Z
\2! _[Z! =%'! ;#89%/8'! 8)#981'! -/8! 0-/8)1! (/%! '8#A9.9'#89-/! =%! .%()!
0#.#=9%2!!
!
KLB!"E#)0#!;)1;#)%!#@8(%..%0%/8!.%!.#/@%0%/8!=?(/%!18(=%!;9D-8!=%!"E#'%!\!R=%)/9<)%! 18#;%! #D#/8! .#! =%0#/=%!
=?#(8-)9'#89-/!=%!09'%!'()!.%!0#)@E1S!=%!O%C-;9M2!Q%!;)-8-@-.%!=%!@%88%!18(=%!#!)%`(!(/!#D9'!;-'989I!=%!.#!;#)8!=%!.#!
HaF!RFood#and#Drug#AdministrationS!%8!=%!.?BGF!REuropean#Medicine#AgencyS,!%8!'%)#!=-/@!@-00(/!#(C!B8#8'3b/9'!
%8!J!.?B()-;%2!!
Q%!.#/@%0%/8! =%!.?18(=%!9/8%)/#89-/#.%!%'8!;)1D(!;-()!.%!=%(C9<0%!'%0%'8)%!=%! U4&52!T.!;-)8%)#!'()!544!;#89%/8'!
#88%9/8'! =%! @#/@%)'! =(! ;-(0-/! V!/-/! J! ;%898%'! @%..(.%'!W!9/D#'9I'!-(!018#'8#'1'!R'8#=%! TTTc! 9/D#'9I! -(! '8#=%! Td!
018#'8#89:(%S! %8! :(9!%C;)90%/8!.%!)1@%;8%()!XQF3FU2! O%C-;9M!'%)#!1D#.(1!@-00%!8)#98%0%/8!=%!=%(C9<0%!.9$/%,!
;-()!=%'!;#89%/8'!'()!.%':(%.'!.%!8)#98%0%/8!=%!;)%09<)%!.9$/%!R@-00%!.#!@E909-8E1)#;9%S!/?#!;#'!181!%II9@#@%!-(!%'8!
0#.! 8-.1)12! Q%'! 8)#D#(C! ;)1;#)#8-9)%'! '-/8! =1>J! %/$#$1'! %8! I9/#/@1',! %/! ;#)89@(.9%)! ;-()! .#! I#A)9@#89-/! =%'! .-8'! =%!
01=9@#0%/8'2!Q%! ;)->%8!=?9/8)-=(@89-/!%/!A-()'%!=?KLB!"E#)0#!#!;-()!-A>%@89I!=%!I9/#/@%)!.%!.#/@%0%/8!=%!@%88%!
18(=%!;9D-8!=%!"E#'%!\!
O%C-;9M!#! -A8%/(! (/!V!'8#8(8!=%!01=9@#0%/8!-);E%.9/!W! #(C! B8#8'3b/9'! ;-()!=%'!;#89%/8'!:(9!-/8!(/!@#/@%)!=(!
;-(0-/!=98!V!/-/!J!;%898%'!@%..(.%'!W!%8!:(9!%C;)90%/8!.%!)1@%;8%()!XQF3FU2!B/!B()-;%,!9.!%'8!@-/'9=1)1!@-00%!(/%!
01=%@9/%! ;%)'-//#.9'1%! ;-()! @%! @#/@%)! =(! ;-(0-/,! @#)! '?#=)%''#/8! J! =%'! ;#89%/8'! )1;-/=%()'! XQF3FU! ;-'989I'2!
7%88%!8E1)#;9%!;%)'-//#.9'1%!%8!@%!'8#8(8!V!-);E%.9/!W!;%)0%88%/8!(/!=1D%.-;;%0%/8!#@@1.1)1!=(!;)-=(982!
!
LE!CANCER!DU!POUMON!AVANCE!:!UN!BESOIN!MEDICAL!FORT!
!
Q%!@#/@%)!=(!;-(0-/!%'8!.%!@#/@%)!.%!;.('!0%()8)9%)!8-(8%'!e-/%'!$1-$)#;E9:(%'!@-/I-/=(%',!#D%@!&,5_!09..9-/!=%!
/-(D%#(C! @#'! =9#$/-'89:(1'! %/! U4&U! %8! &,\[! 09..9-/! =%! =1@<'! %/! U4&U*2! Q#! $)#/=%! 0#>-)981! =%'! ;#89%/8'! /?%'8!
=9#$/-'89:(1%! :(?J! (/! '8#=%! #D#/@1! R'8#=%! TTT! 9/D#'9I! -(! '8#=%! Td! 018#'8#89:(%S! @#)! @%! @#/@%)! ;)1'%/8%! ;%(! =%!
'N0;8^0%'!#(C!'8#=%'!;)1@-@%'!=%!.#!0#.#=9%2!G#.$)1!.%'!=9II1)%/8'!8)#98%0%/8'!=9';-/9A.%'!#(>-()=?E(9!R@E9)()$9%,!
)#=9-8E1)#;9%,!@E909-8E1)#;9%,!8E1)#;9%[email protected]%S,!.%'!8#(C!)%.#89I'!=%!'()D9%!)%'8%/8!8)<'!I#9A.%'!#(!'8#=%!018#'8#89:(%\2!!
A!ce!jour,!sur!la!seule!indication!du!cancer!du!poumon!NSCLC,!OSE!Pharma!estime!le!marché!potentiel!de!Texopi®!
à!environ!2!milliards!d’euros4.!
!
TEXOPI®!APPLICABLE!A!D’AUTRES!CANCERS!EN!PHASE!2!
!
O%C-;9M!;%(8!1$#.%0%/8!%/8)%)!%/!;E#'%!U!=#/'!=?#(8)%'!@#/@%)'!=?9/81)f8!P!.%'!@#/@%)'!=%'!-D#9)%',!=(!@-.-/!%8!=(!
'%9/2! a#/'! @%'! 0#.#=9%',! .%'! 0f0%'! #/89$</%'! 8(0-)#(C! ;)1'%/8'!'-/8!1$#.%0%/8!%C;)901'!%8!'-/8!=%!0#(D#9'!
;)-/-'89@2! Q%! ;)-=(98! '?#=)%''%)#! J! =%'! ;#89%/8'! XQF3FU! ;-'989I',! .%'!;#89%/8'!)1;-/=%()'!#(!8)#98%0%/8,! =-/8! .%!
;)-/-'89@[email protected]/9:(%!%'8!1$#.%0%/8!;1>-)#89I!J!(/!'8#=%!#D#/@12!Q#!'-@9181!;)1D-98!=%!'1.%@89-//%)!#D%@!'%'!%C;%)8',!I9/!
U4&5,! (/%! 18(=%! =%! ;E#'%! U! ;#)09! .%'!@#/@%)'!@981'!%8!=?%C;.-)%)!.%'!#''-@9#89-/'!#D%@!.%'!8)#98%0%/8'!
=?900(/-8E1)#;9%! =%! 8N;%! V!@E%@g;-9/8! 9/E9A98%()'!W! R@%'! /-(D%..%'! 900(/-8E1)#;9%'!#@89D%/8!.%'!@%..(.%'!O!
@N8-8-C9:(%'! =%! I#`-/! /-/! ';1@9I9:(%! %/! .%D#/8! .%'! I)%9/'! :(9! A.-:(%/8! @%'! @%..(.%'S2! Q%! ;)->%8! =?9/8)-=(@89-/!%/!
A-()'%!=?KLB!"E#)0#!D9'%!1$#.%0%/8!J!I9/#/@%)!.%!.#/@%0%/8!=?(/%!18(=%!=%!"E#'%!U2!!
!
a-09/9:(%!7-'8#/89/9,!a9)%@8)9@%!h1/1)#.%!%8!@-3I-/=#8)9@%!=?KLB!"E#)0#,!=1@.#)%!P!V!Les#bons#résultats#de#l’étude#de#
Phase#2# de# notre# produit#Texopi®# appliqué# au#cancer# du#poumon,# constituent#un#espoir# pour# les#patients,#tant# en#
espérance# de# vie# qu’en# qualité# de# vie.# Ce# projet# d’introduction# en# bourse# marque# une# étape# importante# du#
développement#d’OSE#Pharma,#et#permettra#de#mener#à#bien#notre#étude#de#Phase#3#de#Texopi®#dans#cette#maladie.#
Nous#serons#ainsi#en#mesure#d’avancer#vers#la#mise#sur#le#marché#d’une#immunothérapie#T#spécifique#innovante#et#
personnalisée.!W!!
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
U!(Ciuleanu#T#et#al#2012)#(Hanna#N#et#al#2004)#(Garassino#MC#et#al#2013).!!
3#taux#de#survie#à#5#ans#de#1#%#chez#les#patients#métastatiques#American#Cancer#Society#?#Revue#22/05/2013#
4Sur#la#base#d’études#indépendantes#issues#des#études#épidémiologiques#internationales#OMS#?#Globocan#2012#

!
Ne#pas#distribuer#directement#ou#indirectement#aux#Etats?Unis#d’Amérique,#au#Canada,#en#Australie#ou#au#Japon.#
"#$%!\!'()!*#
!
Mise!à!disposition!du!document!de!base!!
a%'!%C%0;.#9)%'!=(!=-@(0%/8!=%!A#'%!%/)%$9'8)1!.%!&]!'%;8%0A)%!U4&*!'-('!.%!/(01)-!.2&*3456!'-/8!=9';-/9A.%'!
'#/'!I)#9'!%8!'()!'90;.%!=%0#/=%!#(!'9<$%!'-@9#.!=?KLB!"E#)0#,!"1;9/9<)%!"#)9'!L#/81!7-@E9/,!U[!A9',!)(%!=(!H#(A-()$!
L#9/8!i#@:(%'!+!]54&*!"#)9',!H)#/@%2!Q%!=-@(0%/8!=%!A#'%!;%(8!f8)%!@-/'(.81!'()!.%'!'98%'!=%!.jF(8-)981!=%'!0#)@E1'!
Rkkk2#0I3I)#/@%2-)$S!%8!=?KLB!"E#)0#!Rkkk2-'%;E#)0#2@-0S2!!
!
Facteurs!de!risques!!
Qj#88%/89-/!=(!;(A.9@!%'8!#889)1%!'()!.%!@E#;98)%!*!V!H#@8%()'!=%!)9':(%'!W!=(!a-@(0%/8!=%!A#'%!%/)%$9'8)1!;#)!.jFGH2!!!
!
A!propos!d’OSE!Pharma!
KLB!"E#)0#!%'8!(/%!'-@9181!A9-;E#)0#@%(89:(%!:(9!@-/`-98!%8!=1D%.-;;%!=%'!;)-=(98'!=?900(/-8E1)#;9%!@-/8)%!.%!@#/@%)!$)l@%!J!'#!
8%@E/-.-$9%! G%0-;9M! :(9! #($0%/8%! .#! )1;-/'%! ';1@9I9:(%! O! @N8-8-C9:(%!%8!#;;)%/=!#(!'N'8<0%!900(/98#9)%!J!1.909/%)!.%'!@%..(.%'!
@#/@1)%('%'2!!
L-/!;)-=(98!;E#)%,!O%C-;9M!RKLB3U&4&S,!%'8!(/%!@-0A9/#9'-/!=%!&4!1;98-;%'!-;8909'1',!=9)9$1'!@-/8)%!5!#/89$</%'!8(0-)#(C!J!.#!I-9'2!
a#/'!'-/!#;;.9@#89-/[email protected]/9:(%!.#!;.('!#D#/@1%,!9.!I%)#!.?-A>%8!=?(/%!18(=%!;9D-8!=%!"E#'%!\!#(C!B8#8'3b/9'!%8!%/!B()-;%,!=#/'!.%!@#/@%)!=(!
;-(0-/!V!/-/! J! ;%898%'! @%..(.%'!W! RmL7Q7S! ;-()! =%'! ;#89%/8'! XQF! FU! ;-'989I'2! O%C-;9! M! #! )%`(! .%! '8#8(8!=%!01=9@#0%/8!-);E%.9/!#(C!
B8#8'3b/9'!%8!%/!B()-;%!%'8!@-/'9=1)1!@-00%!(/%!01=%@9/%!;%)'-//#.9'1%!'()!(/%!;-;(.#89-/!=%!;#89%/8'!)1;-/=%()'!XQF3FU2!!
!
"#)!#9..%()'!O%C-;9M!RKLB3U&4&S!;%(8!f8)%!=1D%.-;;1!%/!"E#'%!U!=#/'!=?#(8)%'!9/=9@#89-/'!8-(>-()'!@E%e!=%'!;#89%/8'!)1;-/=%()'!XQF3!
FU! ;-'989I'!%/!-/@-.-$9%!R-D#9)%',! @-.-/,! '%9/',! ;)-'8#8%S2! T.! %'8! 1$#.%0%/8! %/D9'#$1! %/! @-0A9/#9'-/! #D%@! =?#(8)%'! ;)-=(98'!
=?900(/-8E1)#;9%2!!
!
O%C-;9M!D9'%!@9/:!#/89$</%'!8(0-)#(C!ROFFS2!T.'!-/8!181!'1.%@89-//1'!@#)!.%()!;)1'%/@%!%'8!.91%!J!(/!0#(D#9'!;)-/-'89@!%8!J!.#!$)#D981!=%!
;.('9%()'!@#/@%)'2!Q%!;)-=(98!@-/89%/8!=9C!1;98-;%'!-;8909'1',!=1)9D1'!=%!@%'!@9/:!#/89$</%'!8(0-)#(C,!:(9!$1/<)%/8!=%!I-)8%'!)1;-/'%'!
';1@9I9:(%'!=%!@%..(.%'!O! @N8-8-C9:(%',!@-/=(9'#/8!.%!'N'8<0%!900(/98#9)%!J!1.909/%)! .%'!@%..(.%'!8(0-)#.%'!:(9!%C;)90%/8!.?(/!=%!@%'!
#/89$</%'!8(0-)#(C2!!
!
a%;(9'!U4&U,!KLB!"E#)0#!%'8!$1)1%!;#)!B09.%!Q-)9#!%8!a-09/9:(%!7-'8#/89/9,!=%(C!%/8)%;)%/%()'!%C;1)90%/81'!=%!.#!A9-8%@E/-.-$9%2!Q#!
'-@9181!%'8!A#'1%!J!"#)9',!J!.?E^;98#.!7-@E9/2!B/!U4&*,!.#!'-@9181!#!I9/#.9'1!.?#@:(9'989-/!=%'!#@89I'!=%!.#!8%@E/-.-$9%!G%0-;9M,!=%'!=)-98'!
0-/=9#(C!%8!=(!'#D-9)3I#9)%!@-//%C%2!Q?#@:(9'989-/!=%!G%0-;9M!'%!I-/=%!'()!.?%C;1)9%/@%!=?B09.%!Q-)9#!:(9!#!181,!%/!8#/8!:(?#/@9%/!7BK!
=?B;900(/%,!J!.?9/989#89D%!=(!;#''#$%!%/!=1D%.-;;%0%/[email protected]/9:(%!=%!@%!;)-=(98!/-D#8%()!=%!.?900(/-8E1)#;9%!=(!@#/@%)2!
!
!
Contacts!presse!
!
OSE!Pharma!sa!
a-09/9:(%!7-'8#/89/9,!a9)%@8%()!h1/1)#.!
=-09/9:(%2@-'8#/89/9n-'%;E#)0#2@-0!!
G-A!Y\\!6!&\!U4!]]!*[!!
!
F.%C9'!"%N)-.%',!a9)%@8%()!F=09/9'8)#89I!%8!
H9/#/@9%)!
F.%C9'2;%N)-.%'n-'%;E#)0#2@-0!
G-A!P!Y\\!6!&&!5&!&[!]]!
!
!
!
!
Citigate!Dewe!Rogerson!!
Q#()%/@%!c#(.8!o!Q(@9%!Q#)$(9%)!
Y\\!&!5\!\U!_*!]_!!
.#()%/@%2A#(.8n@989$#8%2I)!!
!
ComCorp!!
H.-)%/@%!"-)8%>-9%!o!F//%!X#)=N!
Y\\!6!__!_*!_&!]*!3!!
I;-)8%>-9%n@-0@-);2I)!
!
Avertissement!:!!
!
Q%! ;)1'%/8! @-00(/9:(1! %8! .%'! 9/I-)0#89-/'! :(?9.! @-/89%/8! /%! @-/'898(%/8! ;#',! /9! /%! '#()#9%/8! f8)%! 9/8%);)181'! @-00%! (/%! -II)%! #(!
;(A.9@!-(!(/%!9/D98#89-/!=%!D%/8%!-(!=%!'-('@)9;89-/,!-(!.#!'-..9@98#89-/!=%!8-(8!-)=)%!-(!9/D98#89-/!=?#@E#8!-(!=%!'-('@)9;89-/!=?#@89-/'!
-(!=?#(8)%'!898)%'!I9/#/@9%)'!KLB!"XFpGF!=#/'!(/!:(%.@-/:(%!;#N'2!F(@(/%!-II)%!=?#@89-/'!-(!#(8)%'!898)%'!I9/#/@9%)'!/?%'8!I#98%,!/9!/%!
'%)#!I#98%!/9! %/!H)#/@%!/9!J! .?18)#/$%),!;)1#.#A.%0%/8!J!.?-A8%/89-/! =?(/! D9'#!=%!.?F(8-)981!=%'! 0#)@E1'!I9/#/@9%)'!R.?!V!AMF!WS!'()!(/!
;)-';%@8('! @-0;-'1! =(! =-@(0%/8! =%! A#'%! -A>%8! =%! @%! @-00(/9:(1! %8! =?(/%! /-8%! =?-;1)#89-/! :(9! '%)#! '-(09'%! (.81)9%()%0%/8! J!
.?FGH,!@-/I-)0%!#(C!=9';-'989-/'!=%!.#!a9)%@89D%!U44\o]&o7B!0-=9I91%2!
!

!
Ne#pas#distribuer#directement#ou#indirectement#aux#Etats?Unis#d’Amérique,#au#Canada,#en#Australie#ou#au#Japon.#
"#$%!*!'()!*#
B/!;#)89@(.9%),!.%!;)1'%/8!@-00(/9:(1!/%!@-/'898(%!;#'!(/%!-II)%!=%!D%/8%!=%'!#@89-/'!-(!#(8)%'!898)%'!I9/#/@9%)'!=%!KLB!"E#)0#!-(!(/%!
:(%.@-/:(%!'-..9@98#89-/!=?-II)%!=?#@E#8!-(!=%!'-('@)9;89-/!=%!898)%'!I9/#/@9%)'!#(C! B8#8'3b/9'!=?F01)9:(%!/9!=#/'!#(@(/!#(8)%!;#N',!N!
@-0;)9'! #(! 7#/=#,! %/! F('8)#.9%! %8! #(! i#;-/2! Q%'! #@89-/',! -(! 8-(8%! #(8)%! D#.%()! 0-A9.9<)%,! =?KLB! "XFpGF! /%! ;%(D%/8! f8)%! -II%)8%',!
'-('@)98%'! -(! D%/=(%'! #(C! B8#8'3b/9'! =?F01)9:(%! :(?J! .#! '(98%! =?(/! %/)%$9'8)%0%/8! %/! D%)8(! =(! b2L2! L%@()989%'! F@8!=%!&[\\,!8%.!:(%!
0-=9I91!RV!U.S.!Securities!Act!WS,!-(!=#/'!.%!@#=)%!=?(/%!%C%0;89-/!J!@%88%!-A.9$#89-/!=?%/)%$9'8)%0%/82!Q%'!#@89-/'!=%! KLB!"XFpGF!
/?-/8! ;#'! 181! %8! /%! '%)-/8! ;#'! %/)%$9'8)1%'! #(! 898)%! =(! b2L2! L%@()989%'! F@8! %8! KLB! "XFpGF! /?#! ;#'! .?9/8%/89-/! =?%/)%$9'8)%)! .?-II)%!
0%/89-//1'!=#/'!.%!;)1'%/8!=-@(0%/8!-(!(/%!;#)89%!=%!@%88%!-II)%!#(C!B8#8'3b/9'!=?F01)9:(%!/9!=%!;)-@1=%)!J!(/%!:(%.@-/:(%!-II)%!#(!
;(A.9@!=%!'%'!#@89-/'!-(!D#.%()'!0-A9.9<)%'!#(C!B8#8'3b/9'!=?F01)9:(%2!
!
Q#!=9II('9-/,!.#!;(A.9@#89-/!-(!.#!=9'8)9A(89-/!=%!@%!@-00(/9:(1!=#/'!@%)8#9/'!;#N'!;%(8!@-/'898(%)!(/%!D9-.#89-/!=%'!=9';-'989-/'!.1$#.%'!
%8! )1$.%0%/8#9)%'! %/! D9$(%()! -(! f8)%! '(>%88%! J! =%'! )%'8)9@89-/'! %/! D%)8(! =%'! =9';-'989-/'! .1$#.%'! %8! )1$.%0%/8#9)%'! %/! D9$(%()2! Q%'!
;%)'-//%'! ;EN'9:(%0%/8! ;)1'%/8%'! =#/'! @%'! ;#N'! %8! %/! ;-''%''9-/! =(! @-00(/9:(1! =-9D%/8! =-/@! '?9/I-)0%)! =%'! 1D%/8(%..%'!
)%'8)9@89-/'!.-@#.%'!%8!'?N!@-/I-)0%)2!Q%!;)1'%/8!@-00(/9:(1!=%!;)%''%!/%!=-98!;#'!f8)%!;(A.91,!8)#/'09'!-(!=9'8)9A(1,!=9)%@8%0%/8!-(!
9/=9)%@8%0%/8,!'()!.%!8%))98-9)%!=%'!B8#8'3b/9'!=?F01)9:(%,!=(!7#/#=#,!=%!.?F('8)#.9%!-(!=(!i#;-/2!
!
Q%! ;)1'%/8! @-00(/9:(1! @-/'898(%! (/%! @-00(/9@#89-/! J! @#)#@8<)%! ;)-0-89-//%.! %8! /-/! ;#'! (/! ;)-';%@8('! #(! '%/'! =%! .#! a9)%@89D%!
U44\o]&o7B!=(!"#).%0%/8!%()-;1%/!%8!=(!7-/'%9.!=(!*!/-D%0A)%!U44\!8%..%!:(%!0-=9I91%,!/-8#00%/8!;#)!.#!a9)%@89D%!U4&4o]\obB!=(!
"#).%0%/8! %()-;1%/! %8! =(! 7-/'%9.! =(! U*! /-D%0A)%! U4&4,! %8! 8%..%! :(%! 8)#/';-'1%! =#/'! @E#@(/! =%'! B8#8'! 0%0A)%'! =%! .?B';#@%!
1@-/-09:(%!%()-;1%/!R.#!V!Directive!Prospectus!WS2!
!
L?#$9''#/8!=%'!B8#8'!0%0A)%'!=%!.?B';#@%!B@-/-09:(%!B()-;1%/!#(8)%'!:(%!.#!H)#/@%,!#N#/8!8)#/';-'1!.#!a9)%@89D%!")-';%@8(',!#(@(/%!
#@89-/!/?#!181!%/8)%;)9'%!%8!/%!'%)#!%/8)%;)9'%!J!.?%II%8!=%!;%)0%88)%!(/%!-II)%!#(!;(A.9@!=%'!898)%'!-A>%8!=%!@%!@-00(/9:(1!/1@%''98#/8!
.#!;(A.9@#89-/!;#)!KLB!"XFpGF!=?(/!;)-';%@8('!=#/'!.?(/!-(!.?#(8)%!=%!@%'!B8#8'!0%0A)%'2!B/!@-/'1:(%/@%,!.%'!#@89-/'!KLB!"XFpGF!
/%!;%(D%/8!f8)%!-II%)8%'!%8!/%!'%)-/8!-II%)8%'!=#/'!#(@(/!=%'!B8#8'!0%0A)%'!#(8)%!:(%!.#!H)#/@%,!'#(I!@-/I-)010%/8!#(C!=1)-$#89-/'!
;)1D(%'! ;#)! .?#)89@.%! \RUS! =%! .#! a9)%@89D%! ")-';%@8(',! '9! %..%'! -/8! 181! 8)#/';-'1%'! =#/'! @%8! B8#8! 0%0A)%! -(! =#/'! .%'! #(8)%'! @#'! /%!
/1@%''98#/8! ;#'! .#! ;(A.9@#89-/! ;#)! KLB! "XFpGF! =?(/! ;)-';%@8('! #(! 898)%! =%! .?#)89@.%! \! =%! .#! a9)%@89D%! ")-';%@8('! %8o-(! =%'!
)<$.%0%/8#89-/'!#;;.9@#A.%'!=#/'!@%8!B8#8!0%0A)%2!!
!
L?#$9''#/8! =(! p-N#(0%3b/9,!@%!@-00(/9:(1! /%! @-/'898(%!;#'!(/%!-II)%! ;(A.9:(%!=%!D#.%()'!0-A9.9<)%'2!T.!'?#=)%''%!(/9:(%0%/8!#(C!
;%)'-//%'! :(9!P! R9S! '-/8! =%'! ;)-I%''9-//%.'! %/! 0#89<)%! =j9/D%'89''%0%/8'! RV!investment# professionnals!WS! #(! '%/'! =%! .j#)89@.%! &[R5S! =(!
H9/#/@9#.! L%)D9@%'! #/=! G#)g%8'! F@8! U444! RH9/#/@9#.! ")-0-89-/S! K)=%)! U445! R8%.! :(j#@8(%..%0%/8! %/! D9$(%(),! @93#;)<'! .%! V! H9/#/@9#.!
")-0-89-/!K)=%)!WS!R.?!V!Ordre!WS,!R99S!'-/8!D9'1%'!J!.j#)89@.%!*[RUS!R#S!J!R=S!RV!high#net#worth#companies,#unincorporated#associations,!%8@2!
WS!=(!H9/#/@9#.!")-0-89-/!K)=%),!R999S!'-/8!%/!=%E-)'!=(!p-N#(0%3b/9,!-(!R9DS!'-/8!=%'!;%)'-//%'!J!:(9!(/%!9/D98#89-/!-(!(/%!9/@98#89-/!J!
'j%/$#$%)!=#/'!=%'! #@89D981'!=j9/D%'89''%0%/8!R#(!'%/'!=%! .#!'%@89-/!U&!=(!H9/#/@9#.! L%)D9@%'!#/=! G#)g%8'!F@8!U444S!=#/'!.%!@#=)%!=%!
.j109''9-/!-(!=%!.#!@%''9-/!=%!8-(8%'!D#.%()'!0-A9.9<)%'!;%(8!f8)%!.1$#.%0%/8!@-00(/9:(1%,!=9)%@8%0%/8!-(!9/=9)%@8%0%/8!R8-(8%'!@%'!
;%)'-//%'!18#/8!=1/-001%'!%/'%0A.%,!.%'!V!"%)'-//%'!X#A9.981%'!WS2!Q%!;)1'%/8!@-00(/9:(1!%'8!=%'89/1!(/9:(%0%/8!#(C!"%)'-//%'!
X#A9.981%'! %8! /%! ;%(8! f8)%! (89.9'1! ;#)! #(@(/%! ;%)'-//%! #(8)%! :(j(/%! "%)'-//%! X#A9.981%2! O-(8! 9/D%'89''%0%/8! -(! #@89D981!
=j9/D%'89''%0%/8!#(:(%.!'%!)#;;-)8%!.%!;)1'%/8!@-00(/9:(1!%'8!#@@%''9A.%!(/9:(%0%/8!#(C!"%)'-//%'!X#A9.981%'!%8!/%!;%(8!f8)%!)1#.9'1!
:(%!;#)!.%'!"%)'-//%'!X#A9.981%'2!
!
Q%! ;)1'%/8! @-00(/9:(1! @-/89%/8! =%'! =1@.#)#89-/'! ;)-';%@89D%'2! F(@(/%! $#)#/89%! /%! ;%(8! f8)%! =-//1%! :(#/8! J! .#! )1#.9'#89-/! =%!@%'!
=1@.#)#89-/'!;)-';%@89D%'!:(9!'-/8!'-(09'%'!J!=%'!)9':(%'!8%.'!:(%,!/-8#00%/8,!@%(C!=1@)98'!=#/'!.%!=-@(0%/8!=%!A#'%!=%!.#!L-@9181!
%/)%$9'8)1!#(;)<'!=%!.?F(8-)981!=%'!0#)@E1'!I9/#/@9%)'!'-('!.%!/(01)-!T2!&*3456!.%!&]!'%;8%0A)%!U4&*,!%8!J!.?1D-.(89-/!=%!.#!@-/>-/@8()%!
1@-/-09:(%,!=%'!0#)@E1'!I9/#/@9%)'!%8!=%'!0#)@E1'!'()!.%':(%.'!KLB!"XFpGF!1D-.(%2!
!
!